https://scholars.lib.ntu.edu.tw/handle/123456789/636678
標題: | Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease | 作者: | Lin, Yi Wen Fang, Chih Hsiang Liang, Ya Jyun Yang, Ching Yun Kuo, W. T. Lin, Feng-Huei |
關鍵字: | Alzheimer’s disease | Amyloid beta | Clenbuterol | Controlled release | Hydroxyapatite | 公開日期: | 1-十二月-2023 | 卷: | 27 | 期: | 1 | 來源出版物: | Biomaterials Research | 摘要: | Background: Alzheimer’s disease is a neurodegenerative disorder, and Aβ aggregation is considered to be the central process implicated in its pathogenesis. Current treatments are faced by challenges such as serious side effects and reduced drug bioavailability. In this study, we developed a drug delivery system for intramuscular injection that uses cellular activity to achieve constant and long-term drug release. Methods: Synthesized mesoporous hydroxyapatite (SHAP) was prepared via co-precipitation, and hydrophobic surface modification using stearic acid was then used to load clenbuterol by physical absorption, thus creating the drug delivery system. Clenbuterol release was achieved through cellular activity, with macrophage uptake triggering lysosome/endosome disruption, cytoplasmic release, extracellular exocytosis, and subsequent systemic circulation. Results: We found that clenbuterol-loaded SHAP enabled sustained release for more than 2 weeks and effectively modulated inflammation, reduced Aβ oligomer-induced toxicity, and prevented Aβ aggregation. Conclusions: Our findings suggest that treatment with clenbuterol loaded in this SHAP delivery system could be a promising strategy for treating Alzheimer’s disease. Graphical Abstract: [Figure not available: see fulltext.]. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/636678 | ISSN: | 1226-4601 | DOI: | 10.1186/s40824-023-00432-4 |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。